Blog Highlights Significant Patent Decisions of the Patent Trial and Appeal Board and the Federal Courts, and Developments Affecting the Life Sciences Industry

SEATTLE, Wash. (May 15, 2018) - Perkins Coie is proud to announce the launch of 1600 PTAB & Beyond, a blog that reports from the intersection of the life sciences industry and key decisions and developments from the Patent Trial and Appeal Board (PTAB), district courts and appellate courts.

Postings will focus on intellectual property (IP) analyses and insights within a practical and actionable context. Topics include:

• Final Written Decisions from the PTAB
• Institution Decisions from the PTAB
• Inter Partes Review (IPR) issues
• Joinder cases
• Obviousness issues
• Prior Art petitions
• PTAB Procedures explaining rules and notices from the Board
• Significant and notable rulings from the federal courts

To read the 1600 PTAB & Beyond blog or to sign up for a customized RSS feed from the blog, please visit https://www.1600ptab.com/.

The primary authors of 1600 PTAB & Beyond (listed alphabetically) are:

Bryan Beel, Ph.D.: counsels clients in patent litigation and IPR proceedings on the most efficient, effective and favorable way to resolve a dispute, with a focus on litigation involving pharmaceutical and biotechnology patents.

Shannon Bloodworth: represents pharmaceutical and biotechnology clients in complex patent litigation and post-grant proceedings. She has extensive experience trying large-scale patent litigation, nationally and internationally, relating to pharmaceutical patents.

Andrew Dufresne, Ph.D.: focuses on patent litigation, regularly practicing before the U.S. Court of Appeals for the Federal Circuit, U.S. District Courts, and the Patent Trial and Appeal Board. His experience also includes advising clients in the chemical, pharmaceutical, and biotechnology industries in obtaining patent protection for their inventions.

Allison Glasunow, Ph.D.: counsels clients on technical and legal matters concerning patentability and developing their patent portfolios in life science matters, with an emphasis in immunotherapy, cellular therapeutics, genetics and genomics, stem cells, cancer and cardiovascular therapies, clinical and research diagnostics, pharmaceuticals and medical devices.

Emily Greb: represents clients in patent infringement suits in a range of technologies in district courts throughout the country, focusing her practice on pharmaceutical and biotechnology patent litigation.

Patrick Morris, Ph.D.: focuses primarily on life sciences and biotechnology patent matters, with a particular emphasis on biologic and small molecule therapeutics. He is experienced with a variety of technologies, including genome editing methods, genetically engineered microorganisms, enzymatic/metabolic pathways and genetic diagnostic methods.

Courtney Prochnow, Ph.D.: represents clients in patent litigation cases in district court, and inter partes review, reexamination, and interference proceedings before the United States Patent and Trademark Office. She provides clients with a broad range of IP services, including patent procurement, strategic patent counseling and due diligence.

Ellen Smith, Ph.D.: counsels life science clients on technical and legal matters concerning inventorship, patentability, due diligence, patent portfolios and freedom to operate. She has written about stem cells for academic journals and presented on the topic of patent eligibility of natural products and diagnostics.

Maria Stubbings: represents clients in biotechnology and pharmaceutical patent litigation and Hatch-Waxman abbreviated new drug application patent infringement disputes.

Yingli Wang: counsels clients on a range of IP services, including patent procurement, patent strategy counseling, due diligence, and patentability and freedom to operate opinion.

Michael Wise: represents clients in patent litigation, post-grant patent proceedings, patent prosecution, global patent portfolio management, patent landscape assessments, freedom to operate and patent due diligence.

Perkins Coie’s IP practice litigates patents in district courts across the United States and before the PTAB. The firm’s IP attorneys also successfully prepare and prosecute patent applications in anticipation of licensing opportunities and potential litigation. The group manages clients’ patent portfolios and provides strategies for strengthening and monetizing these portfolios.

The firm’s patent prosecutors and litigators represent clients across the full range of life sciences technologies, including biotechnology, pharmaceuticals (branded and generic), biologics, biosimilars, chemistry, diagnostics, medical devices and digital health. Several IP attorneys have advanced degrees in molecular biology, chemistry and biophysics, while others actively participate on boards of directors for various life sciences organizations, keeping them at the forefront of industry trends.

Perkins Coie was named the 2018 U.S. News – Best Lawyers® “Law Firm of the Year” in Patent Law, an honor it has received three times in six years - more than any other firm. The firm was also recently recognized as the leading law firm representing America’s largest companies in IP litigation by Corporate Counsel. Perkins Coie regularly ranks among the top ten firms handling post-grant proceedings before the PTAB by Lex Machina and Docket Navigator.

Perkins Coie is a leading international law firm that is known for providing high-value, strategic solutions and extraordinary client service on matters vital to our clients’ success. With more than 1,200 lawyers in offices across the United States and Asia, we provide a full array of corporate, commercial litigation, intellectual property, and regulatory legal advice to a broad range of clients, including many of the world’s most innovative companies and industry leaders as well as public and not-for-profit organizations.

Media Inquiries: Please email Justin Cole, Head of Media Relations.